A. Quintás-Cardama

发表

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

H. Kantarjian, A. Vega-Ruiz, J. Cortes, 2009, Leukemia research.

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.

A. El‐Naggar, A. Quintás-Cardama, G. Lozano, 2011, The Journal of clinical investigation.

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

A. El‐Naggar, V. Pant, Peirong Yang, 2012, Cancer cell.

Tumorigenesis promotes Mdm4-S overexpression

V. Pant, A. Quintás-Cardama, G. Lozano, 2017, Oncotarget.

Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

R. Perez-soler, D. Gibbons, A. Quintás-Cardama, 2011, The New England journal of medicine.

The rise and fall of gatekeeper mutations? The BCR‐ABL1 T315I paradigm

H. Kantarjian, D. Gibbons, J. Cortes, 2012, Cancer.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

H. Kantarjian, T. Manshouri, A. Quintás-Cardama, 2010, Blood.

Homoharringtonine for the treatment of chronic myelogenous leukemia

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2008, Expert opinion on pharmacotherapy.

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

A. Quintás-Cardama, J. Lipton, G. Saglio, 2015, Leukemia.

Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.

M. Sadelain, A. Quintás-Cardama, R. Brentjens, 2007, Human gene therapy.

Mutant FLT 3 : A Direct Target of Sorafenib in Acute Myelogenous Leukemia

M. Konopleva, Z. Estrov, D. Harris, 2008 .

Advances in the therapy of chronic idiopathic myelofibrosis.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, The oncologist.

New JAK2 inhibitors for myeloproliferative neoplasms

A. Quintás-Cardama, S. Verstovsek, A. Quintás-Cardama, 2011, Expert opinion on investigational drugs.

Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2008, Clinical lymphoma & myeloma.

Tyrosine Kinase Inhibitors: The First Decade

J. Cortes, A. Quintás-Cardama, Meetu Agrawal, 2010, Current hematologic malignancy reports.

The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.

V. Pant, A. Quintás-Cardama, G. Lozano, 2012, Blood.

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Experimental non-ATP-competitive therapies for chronic myelogenous leukemia

A. Quintás-Cardama, A. Quintás-Cardama, 2008, Leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Blood.

Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies

D. Gilliland, T. Manshouri, A. Quintás-Cardama, 2008, Leukemia.

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

Targeted therapy for chronic lymphocytic leukemia

A. Quintás-Cardama, S. O'brien, A. Quintás-Cardama, 2009, Targeted Oncology.

What CAR Will Win the CD19 Race?

A. Quintás-Cardama, A. Quintás-Cardama, 2019, Molecular Cancer Therapeutics.

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

M. Ross, A. Lazar, P. Hwu, 2008, Nature Clinical Practice Oncology.

Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts

S. Larson, M. Sadelain, A. Quintás-Cardama, 2007, Clinical Cancer Research.

CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond

A. Quintás-Cardama, A. Quintás-Cardama, 2019, Leukemia & lymphoma.

Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006 .

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

J. Cortes, A. Quintás-Cardama, M. Talpaz, 2012, Leukemia.

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

Z. Estrov, D. Harris, H. Kantarjian, 2011, Investigational New Drugs.

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.

Z. Estrov, H. Kantarjian, J. Cortes, 2009, Blood.

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Imatinib and beyond—exploring the full potential of targeted therapy for CML

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Nature Reviews Clinical Oncology.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

M. Caligiuri, O. Abdel-Wahab, R. Levine, 2013, Blood.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

O. Abdel-Wahab, Z. Estrov, D. Harris, 2013, Blood.

Significance of cytogenetic abnormalities in patients with polycythemia vera

H. Kantarjian, M. Sever, A. Quintás-Cardama, 2013, Leukemia & lymphoma.

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.

Z. Estrov, H. Kantarjian, J. Cortes, 2012, Leukemia research.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Nature Reviews Drug Discovery.

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.

C. Creighton, Z. Estrov, D. Harris, 2011, Cancer research.

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

M. Konopleva, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

H. Kantarjian, J. Cortes, M. Sever, 2009, International journal of hematology.

The JAK kinase inhibitor CP‐690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

Z. Estrov, H. Kantarjian, J. Cortes, 2008, Cancer science.

Experimental therapy in myelofibrosis with myeloid metaplasia

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2006, Expert opinion on investigational drugs.

Standard therapy for patients with myelodysplastic syndromes.

G. Garcia-Manero, A. Quintás-Cardama, M. Cherry, 2011, Clinical lymphoma, myeloma & leukemia.

Fatal Kikuchi-Fujimoto disease: the lupus connection

A. Quintás-Cardama, J. Forteza, M. Fraga, 2003, Annals of Hematology.

Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia

G. Garcia-Manero, A. Quintás-Cardama, K. Hoshino, 2007, Leukemia.

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

A. Baruchel, Abraham I. Bassan, G. Vassal, 2021, European journal of cancer.

New Therapies for Chronic Myeloid Leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2007 .

Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013 .

Early cytogenetic and molecular response during first‐line treatment of chronic myeloid leukemia in chronic phase

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer.

Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells

H. Kantarjian, T. Manshouri, A. Quintás-Cardama, 2006, Cancer science.

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2008, Blood.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Blood.

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Blood.

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007, Cancer.

Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia

A. Quintás-Cardama, S. Verstovsek, R. Mesa, 2007, Current hematologic malignancy reports.

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Leukemia & lymphoma.

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, American journal of hematology.

Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia

H. Kantarjian, A. Quintás-Cardama, L. Abruzzo, 2008, Leukemia.

Evaluation of the l-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2007, Expert opinion on investigational drugs.

Cytogenetically normal acute myeloid leukemia.

A. Quintás-Cardama, 2008, The New England journal of medicine.

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status

Chenyue W. Hu, K. Coombes, Nianxiang Zhang, 2017, Leukemia.

Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop

J. Radich, G. Martinelli, A. Quintás-Cardama, 2011, American journal of hematology.

Monitoring molecular response in chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer.

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2009, Clinical Cancer Research.

The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

M. Konopleva, H. Kantarjian, J. Cortes, 2013, Leukemia research.

Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Clinical lymphoma, myeloma & leukemia.

Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms

A. Quintás-Cardama, S. Verstovsek, A. Quintás-Cardama, 2012, Cancer.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Nature Reviews Drug Discovery.

Closing in on the pathogenesis of the 5q- syndrome

A. Quintás-Cardama, S. Post, A. Quintás-Cardama, 2010, Expert review of anticancer therapy.

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.

A. Quintás-Cardama, A. Quintás-Cardama, 2013, Leukemia research.

Nilotinib-associated vascular events.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012, Clinical lymphoma, myeloma & leukemia.

Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy

O. Abdel-Wahab, R. Levine, H. Kantarjian, 2011 .

Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.

A. Quintás-Cardama, E. Jabbour, A. Quintás-Cardama, 2013, Leukemia research.

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current event‐free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer.

Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2010, Clinical lymphoma, myeloma & leukemia.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2014, Cancer.

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Haematologica.

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.

M. Konopleva, E. Burton, H. Kantarjian, 2013, Clinical lymphoma, myeloma & leukemia.

Optimizing treatment of chronic myeloid leukemia

A. Quintás-Cardama, A. Quintás-Cardama, 2012 .

Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response

A. Quintás-Cardama, E. Jabbour, A. Quintás-Cardama, 2012, Leukemia & lymphoma.

The next generation of therapies for chronic myeloid leukemia.

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2009, Clinical lymphoma & myeloma.

Nilotinib therapy in chronic myelogenous leukemia.

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2007, Drugs of today.

Third-generation tyrosine kinase inhibitors and beyond.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2010, Seminars in hematology.

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

S. Grupp, D. Porter, B. Levine, 2016 .

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer control : journal of the Moffitt Cancer Center.

Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2008, Leukemia research.

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

H. Kantarjian, J. Cortes, T. Manshouri, 2005, Leukemia research.

Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34‐positive compartment

C. Creighton, Yiqun Zhang, J. Cortes, 2012, Cancer.

Acute Myeloid Leukemia Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Haematologica.

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

E. Burton, H. Kantarjian, G. Garcia-Manero, 2008 .

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

A. Quintás-Cardama, S. Post, C. Larsson, 2016, Blood Cancer Journal.

New Drugs for Chronic Myelogenous Leukemia

A. Quintás-Cardama, F. P. Santos, A. Quintás-Cardama, 2011, Current hematologic malignancy reports.

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2014, Clinical lymphoma, myeloma & leukemia.

Azacitidine for the treatment of myelodysplastic syndrome

J. Cortes, A. Quintás-Cardama, V. Cataldo, 2009, Expert review of anticancer therapy.

Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

E. Estey, M. Konopleva, Z. Estrov, 2010 .

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2011 .

Predicting survival of patients with hypocellular myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2012, Cancer.

Decitabine and Gemtuzumab Ozogamicin In Patients with Advanced Myelofibrosis

M. Andreeff, H. Kantarjian, A. Quintás-Cardama, 2010 .

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, American journal of hematology.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Blood.

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

E. Burton, H. Kantarjian, G. Garcia-Manero, 2011, Clinical lymphoma, myeloma & leukemia.

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy

D. Gibbons, A. Quintás-Cardama, N. Donato, 2014, Proceedings of the National Academy of Sciences.

Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Expert opinion on pharmacotherapy.

Management of patients with resistant or refractory chronic myelogenous leukemia.

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2008, Oncology.

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Cancer.

Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?

A. Quintás-Cardama, S. Verstovsek, 2007, Leukemia & lymphoma.

Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1T315I and other mutants compared to direct sequencing of the ABL1 kinase domain

A. Quintás-Cardama, M. Talpaz, J. Cortes, 2008, Leukemia.

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.

Xuelin Huang, Jorge Cortes, H. Kantarjian, 2014, Clinical lymphoma, myeloma & leukemia.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2013, OncoTargets and therapy.

Flying under the radar: the new wave of BCR–ABL inhibitors

Jorge Cortes, H. Kantarjian, J. Cortes, 2007, Nature Reviews Drug Discovery.

Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.

J. Bruzzi, H. Kantarjian, G. Garcia-Manero, 2006 .

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.

Susan O'Brien, Jorge Cortes, Moshe Talpaz, 2007, Blood.

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission.

Z. Estrov, J. Cortes, A. Quintás-Cardama, 2013, Clinical lymphoma, myeloma & leukemia.

Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2009, Bone Marrow Transplantation.

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Z. Estrov, J. Cortes, A. Quintás-Cardama, 2012 .

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006 .

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2006, Seminars in thrombosis and hemostasis.

Ponatinib in Philadelphia chromosome-positive leukemias.

A. Quintás-Cardama, A. Quintás-Cardama, 2014, The New England journal of medicine.

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

H. Kantarjian, A. Quintás-Cardama, C. Chuah, 2012 .

Granulocytic sarcoma with massive scalp involvement

A. Quintás-Cardama, S. Verstovsek, H. Amin, 2008, American journal of hematology.

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.

Franziska Michor, Mithat Gonen, Susan Branford, 2011, Blood.

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia research.

The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-α-expressing cells through caspase-3-mediated cleavage of Mcl-1

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Leukemia.

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.

H. Kantarjian, J. Cortes, T. Manshouri, 2006, Leukemia research.

Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Jorge Cortes, J. Cortes, A. Quintás-Cardama, 2009, Blood.

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

H. Kantarjian, D. Gibbons, J. Cortes, 2007 .

Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia

A. Quintás-Cardama, M. Pérez-Encinas, S. González, 1999, Annals of Hematology.

Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

C. Cleeland, H. Kantarjian, G. Garcia-Manero, 2013 .

Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2014 .

Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

R. Munden, J. Bruzzi, H. Kantarjian, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pulmonary Hypertension Is a Frequent Event in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2010 .

ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells

A. Quintás-Cardama, N. Donato, W. Bornmann, 2010, Leukemia.

Primary extramedullary myeloid tumor of the breast: a case report and review of the literature

A. Quintás-Cardama, J. Forteza, M. Fraga, 2003, Annals of Hematology.

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2006 .

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

M. Konopleva, Z. Estrov, D. Harris, 2008, Journal of the National Cancer Institute.

Chemical and clinical development of darinaparsin, a novel organic arsenic derivative.

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2008, Anti-cancer agents in medicinal chemistry.

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.

K. Coombes, C. Creighton, Nianxiang Zhang, 2015, Clinical lymphoma, myeloma & leukemia.

Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer

I. Wistuba, Peirong Yang, A. Quintás-Cardama, 2014, The Journal of pathology.

The p53–Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity

V. Pant, A. Quintás-Cardama, G. Lozano, 2013, Genes & development.

Therapy with azanucleosides for myelodysplastic syndromes

G. Garcia-Manero, A. Quintás-Cardama, F. P. Santos, 2010, Nature Reviews Clinical Oncology.

Synthetic T cell receptor-based lymphocytes for cancer therapy.

A. Quintás-Cardama, D. Getts, R. Hofmeister, 2019, Advanced drug delivery reviews.

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

T. McDonnell, M. Andreeff, A. Quintás-Cardama, 2014, Cancer science.

The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome

A. Quintás-Cardama, C. Larsson, G. Côté, 2013, Molecular Cancer Research.

Through the open door: Preferential binding of dasatinib to the active form of BCR‐ABL unveiled by in silico experiments

D. Gibbons, A. Quintás-Cardama, E. Laurini, 2013, Molecular oncology.

New agents in the treatment of chronic myelogenous leukemia.

A. Quintás-Cardama, J. Pinilla-Ibarz, A. Quintás-Cardama, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation

J. Cortes, A. Quintás-Cardama, N. Donato, 2008 .

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2008, Future oncology.

Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2008, Clinical Cancer Research.

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Future oncology.

Chronic myeloid leukemia: diagnosis and treatment.

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2006, Mayo Clinic proceedings.

Kinase inhibitors in chronic myelogenous leukemia.

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2006, Clinical advances in hematology & oncology : H&O.

A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Leukemia.

hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

M. McArthur, A. Multani, T. Manshouri, 2015, Cancer cell.

Novel approaches in the treatment of systemic mastocytosis

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Nature Reviews Drug Discovery.

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Leukemia.

p53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesis

A. Quintás-Cardama, G. Lozano, T. Terzian, 2010, Oncogene.

Regulation of p53 Activity and Associated Checkpoint Controls

A. Quintás-Cardama, G. Lozano, S. Post, 2010 .

Evolution of Therapies for Chronic Myelogenous Leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer journal.

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005, Blood.

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Blood.

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib

Franziska Michor, Mithat Gonen, Susan Branford, 2014, Haematologica.

A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Arnold J Levine, Vinod Pant, Guillermina Lozano, 2010, Cancer cell.

Prognostic Impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

V. Pant, A. Quintás-Cardama, S. Post, 2010, Oncotarget.

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

V. Pant, T. Iwakuma, A. Quintás-Cardama, 2011, Proceedings of the National Academy of Sciences.

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

A. Quintás-Cardama, S. Verstovsek, A. Quintás-Cardama, 2013, Clinical Cancer Research.

Experimental therapeutics for patients with myeloproliferative neoplasias

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer.

Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis

A. Quintás-Cardama, S. Verstovsek, N. Jain, 2011, Cancer.

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia

G. Garcia-Manero, A. Quintás-Cardama, F. P. Santos, 2011, Leukemia.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Targeted Therapy in Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Therapeutic options for patients with clonal and idiopathic hypereosinophia

J. Cortes, A. Quintás-Cardama, A. Quintás-Cardama, 2008, Expert opinion on investigational drugs.

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2007, Cancer.

CAR T-Cell Therapy in Large B-Cell Lymphoma.

A. Quintás-Cardama, A. Quintás-Cardama, 2018, The New England journal of medicine.

Biology of Chronic and Acute Myeloid Leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2008 .

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

Z. Estrov, D. Harris, H. Kantarjian, 2008, Clinical Cancer Research.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

P. Qiu, M. Konopleva, M. Andreeff, 2016, American journal of hematology.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Blood.

Bone marrow fibrosis and gelatinous atrophy associated with acute Epstein–Barr virus infection

A. Quintás-Cardama, A. Nguyen, D. Maselli, 2008, American journal of hematology/oncology.

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Idecabtagene Vicleucel in Relapsed Myeloma.

A. Quintás-Cardama, 2021, New England Journal of Medicine.

Important Therapeutic Targets in Chronic Myelogenous Leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2007, Clinical Cancer Research.

Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia.

Z. Estrov, J. Cortes, A. Quintás-Cardama, 2013, Clinical lymphoma, myeloma & leukemia.

Toward Engineered Cells as Transformational and Broadly Available Medicines for the Treatment of Cancer

A. Quintás-Cardama, N. Sheppard, A. Hoos, 2018 .

Investigational immunotherapeutics for B-cell malignancies.

A. Quintás-Cardama, S. O'brien, W. Wierda, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia

H. Kantarjian, G. Martinelli, A. Quintás-Cardama, 2013, Cancer.

Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

A. Quintás-Cardama, S. Verstovsek, E. Freireich, 2006, Hematological oncology.

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012, Haematologica.

Erratum: Quintás‐cardama A, Kantarjian H, Garcia‐Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007;109(2):248–55.

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2007 .

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO‐406

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Cancer science.

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

E. Burton, H. Kantarjian, J. Cortes, 2011 .

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

A. Quintás-Cardama, V. Bollu, E. Wu, 2013, Journal of medical economics.

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.

G. Garcia-Manero, A. Quintás-Cardama, V. Richon, 2006, Blood.

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

M. Konopleva, E. Burton, H. Kantarjian, 2011 .

Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy

J. Cortes, A. Quintás-Cardama, L. Abruzzo, 2007, Leukemia.

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012 .

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

M. Konopleva, E. Burton, H. Kantarjian, 2011 .

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Challenges and Progress in the Treatment of Adults with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006 .

Granulocyte–colony‐stimulating factor (filgrastim) may overcome imatinib‐induced neutropenia in patients with chronic‐phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Cancer.

Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

chronic myelogenous leukemia significance of deletions of derivative chromosome 9 in patients with Imatinib mesylate therapy may overcome the poor prognostic

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2013 .

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012 .

therapy reveal treatment effects on leukemic stem cells Dynamics of chronic myeloid leukemia response to long-term targeted

M. Gonen, H. Kantarjian, F. Michor, 2011 .

Management of Cytopenias With Ruxolitinib Treatment in Patients With Myelofibrosis

A. Quintás-Cardama, S. Verstovsek, R. Mesa, 2013 .

Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.

J. Cortes, A. Quintás-Cardama, H. Kantarjian, 2012, Drugs of today.

Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Dasatinib-Induced Platelet Dysfunction.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2007 .

p53 pathway dysfunction in AML: beyond TP53 mutations

A. Quintás-Cardama, S. Kornblau, S. Post, 2017, Oncotarget.

Disorders & Genetic Reports

A. Quintás-Cardama, J. McCarthy, A. Quintás-Cardama, 2013 .

Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia.

H. K. Dai, J. Radich, G. Garcia-Manero, 2009, Leukemia research.

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

H. Kantarjian, J. Cortes, M. Sever, 2013, Leukemia & lymphoma.

The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.

M. Andreeff, H. Kantarjian, A. Quintás-Cardama, 2012, Anticancer research.

Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI)

C. Cleeland, H. Kantarjian, J. Cortes, 2011 .

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy

E. Burton, H. Kantarjian, J. Cortes, 2011 .

Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Original article The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

A. Quintás-Cardama, V. Bollu, E. Wu, 2013 .

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma

A. Quintás-Cardama, A. Quintás-Cardama, 2018, Oncotarget.

Treatment of systemic mastocytosis with denileukin diftitox

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2007, American journal of hematology.

JAK2 inhibitors in polycythemia vera.

A. Quintás-Cardama, 2011, Clinical advances in hematology & oncology : H&O.

Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2010, Current opinion in investigational drugs.